Main content of this page

Anchor links to the different areas of information in this page:

You are here: MEDICA Portal. MEDICA Magazine. Archive. Cells.

Strategy for Identifying Biomarkers

Strategy for Identifying Biomarkers

Very soon a small finger-prick may provide the basis for the reliable diagnosis and characterisation of a vast variety of cancer types. Present-day diagnosis methods, which detect tumour antigens in the blood, often yield false results. Not only is this expensive, but patients must also subsequently undergo painful biopsies.

In contrast, the diagnosis method for prostate cancer, presented after five years of research by an interdisciplinary group of scientists from ETH Zurich, University Hospital Zurich and the Cantonal Hospital of St.Gallen, is highly precise.

The researchers’ work also offers a generally applicable strategy for identifying biomarkers. This also brings the early diagnosis of other cancer types within reach. Moreover, the biomarker pattern contains information about the type of tumour, which helps to ascertain the best possible therapy to be adopted.

The scientists’ approach in their search for biomarker patterns indicating prostate cancer was extremely focused. The starting point for the research work was the “Pten” gene, which is inactivated in 60 percent of all prostate cancer patients and leads, for example, to uncontrolled cell growth.

These enabled the researchers to ensure a high probability that the subsequent steps, which were carried out in mice as a model organism, would also be relevant to humans. In the first step, the scientists inactivated the “Pten” gene specifically in the mouse prostate. They then identified hundreds of prostate surface proteins in healthy mice, and also in those mice which had developed prostate cancer due to the inactivated gene.

Next the researchers compared the protein sets from the healthy mice with those from the cancerous mice. From this they determined a pattern of proteins that is typical of the mutated version of “Pten” and thus also for prostate cancer.

In the second step, the scientists wanted to find out whether the findings from the mouse model were also relevant to humans. They did this by examining tissue and serum samples from prostate cancer patients and a control group. Based on the list of specific proteins drawn up using the mouse model, the researchers identified 39 corresponding proteins in the humans that indicated prostate cancer. The information scientists used more than 20,000 models to calculate the four proteins that enabled the most reliable diagnosis to be made.

“We then used this biomarker pattern to examine a cohort of patients whose blood had never previously been analysed. We were able to predict with precision, stability and reproducibility whether they were suffering from prostate cancer”, says Wilhelm Krek, professor of Cell Biology at ETH Zurich. Of course, this new biomarker signature needs now be to further validated in a larger clinical trial.

The biomarker strategy is based on the concept that the onset of cancer triggered by a mutation, such as the inactivation of a gene, is associated with a change in the protein pattern in the affected organ. Since approximately 20 percent of the surface proteins of certain tissues, including the prostate, can be separated off and detected in the serum, the detection of this kind of protein pattern, which is specific to the illness, represents a reliable potential method of diagnosis.

MEDICA.de; Source: ETH Zürich

 
 

More informations and functions

 
© Messe Düsseldorf printed by www.MEDICA.de